SCM
RLMD icon

Squadron Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Squadron Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.9M Sell
7,350,000
-1,124,571
-13% -$7.86M 15.78% 1
2026
Q1 		$59M Buy
8,474,571
+1,774,571
+26% +$8.4M 21.61% 1
2025
Q4 		$32.4M Buy
+6,700,000
New +$22.4M 13.71% 1

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squadron Capital Management's RLMD Position: Q2 2026 in Review

Squadron Capital Management reduced its Relmada Therapeutics (RLMD) stake by 13% in Q2 2026, selling an estimated $7.86M and leaving 7,350,000 shares worth $50.9M. The position accounts for 15.78% of the portfolio, ranked #1.

Squadron Capital Management first reported a position in RLMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $59M in Q1 2026. 127 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Squadron Capital Management held 7,350,000 shares of Relmada Therapeutics worth $50.9M as of Q2 2026.
  • Squadron Capital Management sold 1,124,571 Relmada Therapeutics shares in Q2 2026, an estimated $7.86M.
  • Relmada Therapeutics made up 15.78% of Squadron Capital Management's portfolio in Q2 2026, its #1 holding.
  • Squadron Capital Management first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Squadron Capital Management's Relmada Therapeutics position peaked at $59M in Q1 2026.
  • 127 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.